

CLAIM AMENDMENTS

1 1. (Currently amended) A pharmaceutical formulation,
2 packaged into a sachet and administered orally after dispersing in
3 water at therapeutic doses which comprises:

4 (a) alendronate microparticles coated with a polymer
5 soluble at a gastric pH of 1 to 4, but insoluble at a salivary pH
6 of 6 - 7.5, and uncoated alginic acid or sodium alginate or
7 admixtures thereof in an amount therapeutically effective to
8 prevent esophageal reflux, heartburn and esophagitis in a patient
9 taking alendronate, where

10 (b) alendronate dissolves in 900 ml 0.1 N HCl at the rate
11 of not less than 85% of within 30 minutes at the range of pH 1 - 4,

12 (c) the dispersion in a glass of 250 ml. water at the
13 degree of 25°C contains no dissolved alendronate at pH 6 - 7.5 or
14 at the most 10% w/v of alendronate dissolved in 3 minutes.

1 2. (Original) The pharmaceutical formulation as claimed
2 in claim 1, comprises lubricants, diluents, flavors and sweeteners
3 or their mixture thereof.

1 3. (Previously presented) The pharmaceutical formulation
2 as claimed in claim 2, where in the diluent is selected from the
3 group consisting of lactose and microcrystalline cellulose or
4 admixtures thereof.

DO NOT ENTER: /T.M./